Another study in the context of ovarian cancer reported that a VGSC-targeting drug, lidocaine, hinders the metastatic capabilities of ovarian cancer by impeding Nav1.5-mediated EMT and the focal adhesion kinase/Paxillin signaling pathway [144]. Here, SCN5A is linked to ovarian carcinoma.